April 09, 2026

Tony Hyman starts as EMBL Director General

Tony Hyman starts as EMBL Director General

Former EMBL group leader returns to lead the organisation’s six sites at a time of change and opportunity in life sciences

Tony Hyman starts as EMBL’s new Director General on 31 March 2026. Credit: Sven Döring

EMBL welcomes its new Director General, Tony Hyman, who will take up the mandate of leading EMBL’s six sites as the organisation enters its next phase.

Hyman succeeds Interim Director Ewan Birney, who assumed leadership following the death of Interim Director General Peer Bork in January. Together, they led EMBL after former Director General Edith Heard departed to become Director and Chief Executive of the Francis Crick Institute in London.

Hyman has had a long-standing relationship with EMBL, having served as a group leader and visiting senior scientist at EMBL Heidelberg from 1993 to 1999. He is also one of four founding directors of the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden, Germany, and holds a professorship of Molecular Biology at Technische Universität Dresden. His research focuses on the role of biological condensates and phase separation in health and disease.

“This is a moment when biology is changing rapidly,” said Hyman. “Advances in imaging, large-scale data generation, and artificial intelligence are reshaping how we study living systems. EMBL has played an important role in previous periods of change, and I look forward to working with colleagues across the organisation as it enters this next phase.”

Our latest News

discover more
A Vaccine for Parkinson’s?

A Vaccine for Parkinson’s?

The Parkinson Foundation has awarded three Innovation Prizes for 2026, including—for the first time—the Manfred Moggert-Kemper Prevention Prize. Prof. Dr. Chi Wang Ip and Assistant Professor Dr. Rhonda McFleder from the Department of Neurology at the University Hospital of Würzburg (UKW), as well as Prof. Dr. Mathias Munschauer from the University Hospital of Heidelberg (UKHD), […]

Study from Heidelberg: Does Targeted Preparation Help with Recovery After Colon Cancer Surgery?

Study from Heidelberg: Does Targeted Preparation Help with Recovery After Colon Cancer Surgery?

Do patients recover more quickly after colorectal cancer surgery if they have previously completed a structured preparatory program? Researchers at Heidelberg University’s Faculty of Medicine and Heidelberg University Hospital are investigating this question in the newly launched PREHAB-PEER study. The Federal Ministry of Research, Technology, and Space is funding the project with approximately 3.45 million […]

Building Better Sandwich Immunoassays: A Toolbox for Biopharma Development Teams

Building Better Sandwich Immunoassays: A Toolbox for Biopharma Development Teams

Immunoassay development used to just mean getting a classic plate-based ELISA up and running. Today, that “standard” ELISA has exploded into many antibody pair-based formats, from homogeneous TR‑FRET assays to multiplexed MSD or Luminex panels—each with its own advantages and pitfalls. The data these assays generate is more robust than ever, but so is the […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp